French drugmaker Sanofi-Aventis SA clinched its long-sought deal for Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group's drugs. The deal's announcement, marks the second-biggest
Read this post on pharmablockbusters.blogspot.com